Corvus Pharmaceuticals 過去の業績
過去 基準チェック /06
Corvus Pharmaceuticals は平均年間 0.5% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。19.1% です。
主要情報
0.5%
収益成長率
16.9%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -458.0% |
| ネット・マージン | n/a |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Corvus Pharmaceuticals: The Market Likes The Story
Nov 13Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29収支内訳
収支内訳
Corvus Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -57 | 8 | 17 |
| 30 Jun 24 | 0 | -23 | 7 | 16 |
| 31 Mar 24 | 0 | -25 | 7 | 16 |
| 31 Dec 23 | 0 | -27 | 7 | 17 |
| 30 Sep 23 | 0 | -30 | 7 | 17 |
| 30 Jun 23 | 0 | -39 | 7 | 23 |
| 31 Mar 23 | 0 | -41 | 7 | 24 |
| 31 Dec 22 | 0 | -41 | 8 | 24 |
| 30 Sep 22 | 0 | -41 | 8 | 25 |
| 30 Jun 22 | 0 | -37 | 8 | 22 |
| 31 Mar 22 | 0 | -40 | 8 | 26 |
| 31 Dec 21 | 0 | -43 | 9 | 29 |
| 30 Sep 21 | 0 | -7 | 10 | 32 |
| 30 Jun 21 | 0 | -6 | 11 | 31 |
| 31 Mar 21 | 0 | -5 | 12 | 30 |
| 31 Dec 20 | 0 | -6 | 12 | 32 |
| 30 Sep 20 | 0 | -44 | 12 | 34 |
| 30 Jun 20 | 0 | -46 | 11 | 36 |
| 31 Mar 20 | 0 | -48 | 11 | 39 |
| 31 Dec 19 | 0 | -47 | 11 | 38 |
| 30 Sep 19 | 0 | -46 | 11 | 37 |
| 30 Jun 19 | 0 | -46 | 11 | 37 |
| 31 Mar 19 | 0 | -44 | 11 | 36 |
| 31 Dec 18 | 0 | -47 | 11 | 39 |
| 30 Sep 18 | 0 | -48 | 10 | 40 |
| 30 Jun 18 | 0 | -51 | 10 | 42 |
| 31 Mar 18 | 0 | -54 | 10 | 45 |
| 31 Dec 17 | 0 | -56 | 10 | 46 |
| 30 Sep 17 | 0 | -55 | 10 | 46 |
| 30 Jun 17 | 0 | -52 | 10 | 43 |
| 31 Mar 17 | 0 | -46 | 9 | 37 |
| 31 Dec 16 | 0 | -36 | 8 | 29 |
| 30 Sep 16 | 0 | -31 | 7 | 24 |
| 30 Jun 16 | 0 | -24 | 5 | 19 |
| 31 Mar 16 | 0 | -36 | 4 | 14 |
| 31 Dec 15 | 0 | -31 | 2 | 11 |
| 30 Sep 15 | 0 | -25 | 1 | 6 |
質の高い収益: CRVSは現在利益が出ていません。
利益率の向上: CRVSは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CRVSは利益を出していないが、過去 5 年間で年間0.5%の割合で損失を削減してきた。
成長の加速: CRVSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: CRVSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。
株主資本利益率
高いROE: CRVSは現在利益が出ていないため、自己資本利益率 ( -458% ) はマイナスです。